Liver cancer is among the deadliest cancers worldwide, and China carries the heaviest share of that burden — roughly 42% of new cases and 41% of deaths. That enormous caseload has given the hepatobiliary surgery and interventional departments of China's major hospitals exceptionally deep experience in resection, TACE (transarterial chemoembolization), and radiofrequency/microwave ablation; and in the era of immunotherapy plus anti-angiogenic therapy, the first-line drug regimens accessible in China are in step with international guidelines — at markedly lower prices.
One thing must be stated first, however: liver transplantation — one of the best curative options for early liver cancer — is essentially not feasible for foreign patients in China. The barrier is regulation, not surgical skill (details below). This article is therefore about coming to China for non-transplant liver cancer treatment: resection, ablation, interventional radiology, and systemic drugs. Any plan must rest on a clear diagnosis, staging, and liver-function assessment; if those are not yet settled, the correct first step is a remote records review — not booking a flight.
What China's Liver Cancer Burden Means for Patients
According to the International Agency for Research on Cancer (IARC, GLOBOCAN 2022), the world recorded about 866,000 new liver cancer cases and about 759,000 deaths in 2022. Of those, about 368,000 new cases (42.4% of the global total) and about 317,000 deaths (41.7%) occurred in China — the heaviest liver cancer burden of any country. Within China, primary liver cancer ranks fifth in incidence and second among cancer deaths; most cases are linked to chronic hepatitis B.
For international patients, the practical meaning is this: the hepatobiliary surgery, interventional radiology, and medical oncology departments of China's major hospitals handle a high volume of liver cancer across the entire spectrum — laparoscopic resection and microwave ablation for early tumors, TACE for mid-stage disease, and combination therapy for advanced cases. That does not mean "any hospital will do" — quality still depends on the specific institution and team — but caseload does translate into experience with complications and with sequencing multi-stage treatment. For more on why patients consider China for cancer care, see this 2026 guide; for how to pick a hospital, see the 2026 top cancer hospitals guide for international patients.
First, Get the Diagnosis Right: Not All "Liver Cancer" Is the Same
"Liver cancer" covers several different diseases with very different treatments and outlooks. Hepatocellular carcinoma (HCC) is the most common primary liver cancer, roughly 75–85% of primary cases, and is the main subject of this article. Other primary liver cancers — notably intrahepatic cholangiocarcinoma — respond to different drug classes and follow different pathways. Metastatic liver cancer (cancer that has spread to the liver from elsewhere) is treated according to the original cancer's playbook and is outside the scope of this article.
HCC usually does not require a needle biopsy for diagnosis: when contrast-enhanced CT or MRI shows the typical pattern in a cirrhotic or hepatitis-B background, national and international guidelines allow a clinical diagnosis; alpha-fetoprotein (AFP) and other blood markers play a supporting role. Diagnosis, staging (usually BCLC), and liver-function assessment (Child-Pugh) together determine the treatment choice — and those are exactly the three things you should provide for a remote evaluation.
Early-Stage Liver Cancer: Resection and Ablation
For patients with localized tumors and adequate liver function, the curative options are surgical resection or ablation. Chinese hepatobiliary surgeons operate at high annual volume, and minimally invasive laparoscopic approaches are routine — a good fit for solitary tumors with adequate liver reserve. Ablation (radiofrequency, RFA, or microwave, MWA) destroys the tumor percutaneously under image guidance, with small trauma, quick recovery, and short hospital stays; microwave ablation is particularly widely used in China. For small tumors of roughly 2–3 cm, ablation stands alongside resection as a curative option (the consensus of Chinese and international guidelines); larger, multiple, or awkwardly located tumors call for a multidisciplinary decision.
Mid-Stage Liver Cancer: TACE (Transarterial Chemoembolization)
TACE is the standard treatment for mid-stage (BCLC-B) liver cancer. A catheter is threaded from the femoral artery into the liver artery branches feeding the tumor; chemotherapy is delivered first, then the vessel is embolized with iodized oil or microspheres — starving the tumor while concentrating the drug locally. Most patients need 2–4 or more repeat sessions, each with a hospital stay of roughly 3–7 days.
The benefit of China's high caseload shows up most directly here: fluency in superselective catheterization, command of embolic materials (iodized oil, microspheres, drug-eluting beads), and experience combining TACE with ablation or with targeted-plus-immunotherapy drugs. On cost, public ranges put a single TACE session at about ¥10,000–20,000 (about US$1,400–2,800), higher when drug-eluting beads or imported consumables are used.
Advanced Liver Cancer: Targeted Plus Immunotherapy
Systemic therapy for unresectable or advanced HCC has moved from sorafenib monotherapy into the era of "immunotherapy plus anti-angiogenic" combinations. After the IMbrave150 trial established atezolizumab plus bevacizumab (T+A) as the first-line standard, China's drug regulator approved the combination in October 2020 for previously untreated unresectable hepatocellular carcinoma. Domestic combinations — sintilimab plus a bevacizumab biosimilar ("Shuangda") and camrelizumab plus apatinib ("Shuang'ai") — are also first-line recommendations in Chinese and international guidelines, and lenvatinib, alone or combined with PD-1 inhibitors, is widely used in China.
These regimens have a well-mapped side-effect profile (immune hepatitis, skin reactions, hypertension, bleeding risk), with established management protocols — but they require a hospital able to handle inpatient complications, which is why this article keeps stressing "choose an experienced center."
Indicative Costs of the Main Systemic Options
| Regimen | Positioning | Indicative self-pay cost |
|---|---|---|
| Atezolizumab + bevacizumab (T+A) | First-line standard (approved) | One cycle every 3 weeks; list prices have fallen sharply after national reimbursement negotiations — annual drug costs typically on the order of tens of thousands to just over 100,000 CNY (about US$7,000–17,000) |
| Sintilimab + bevacizumab biosimilar (Shuangda) | First-line recommendation (approved) | Domestic combinations cost less — annual drug costs can be as low as a few tens of thousands of CNY |
| Lenvatinib (± PD-1 inhibitor) | First-line option / common combination | On the order of several thousand CNY per month after reimbursement negotiations |
A few notes: atezolizumab's launch list price was about ¥13,000 per 1,200 mg vial — by itself roughly ¥220,000 per year at a 3-week cycle; prices have fallen substantially through national reimbursement negotiations. International patients generally cannot use Chinese insurance and self-pay at hospital list prices, so the ranges above are order-of-magnitude references only — confirm actual prices with the hospital pharmacy. Comparable regimens in the United States commonly exceed US$100,000 per year.
Indicative Costs of Local Therapies
| Treatment | Typical use | Indicative self-pay cost |
|---|---|---|
| TACE | Mainly mid-stage (BCLC-B) | about ¥10,000–20,000 per session (about US$1,400–2,800) |
| Radiofrequency / microwave ablation | Early small tumors | about ¥10,000–25,000 per session (about US$1,400–3,500) |
| Surgical resection | Early stage, adequate liver function | total cost usually in the tens of thousands of CNY; complex surgery can exceed ¥100,000 |
These are order-of-magnitude references from public ranges; imported consumables, the number and position of tumors, and length of stay all move the final bill. TACE and ablation are often repeated — budget by course of treatment, not by single session.
About Liver Transplant: The Honest Reality
For qualifying early-stage liver cancer, transplantation removes the tumor and the cirrhotic liver at once and is among the best curative options. But international patients must be told plainly: coming to China for a liver transplant is essentially not feasible.
The legal framework: the Regulations on Human Organ Transplantation, in force since May 2007 (continued and tightened by the Regulations on Human Organ Donation and Transplantation from May 2024), ban organ sales and explicitly target "transplant tourism"; organs donated after death are allocated through the national unified system by medical criteria.
The practical result: the queue of Chinese patients waiting for a liver is already long, and the allocation system does not let foreign patients jump it — cases of foreign patients actually receiving organs from deceased Chinese donors are extremely rare.
Living donation: the law allows only a spouse, lineal blood relatives, or collateral relatives within three generations (or persons with a proven long-term caring relationship) to donate — most foreign patients have no qualifying relative in China, so this path is closed too.
The conclusion is direct: if your disease is suitable for transplantation, seek it in your home country or in other countries/regions open to international patients. China's realistic offering is the non-transplant treatment described above. Any intermediary claiming you can "come to China and wait for an organ" should be treated as a red flag.
Who Should Consider Coming to China
Patients already diagnosed with HCC, with complete imaging and lab records, seeking a second opinion or more cost-effective resection, ablation, TACE, or systemic therapy.
Mid-stage patients facing multiple TACE sessions, who care about interventional experience and total cost.
Advanced patients needing T+A or domestic targeted-immunotherapy combinations, where home prices are prohibitive or drugs are unapproved.
Hepatitis-B-background patients who want hepatology and oncology to manage antiviral and anti-cancer treatment together.
Conversely, if transplantation is the goal, or the disease has reached a terminal stage centered on supportive care, the benefit of crossing borders is usually limited — a remote evaluation first is the pragmatic move.
Care Pathway and Timeline
Remote consultation and records review: assemble contrast-enhanced CT/MRI imaging, diagnosis records, AFP and other lab results, liver-function data, and medication history; a Chinese hepatobiliary oncologist makes a preliminary assessment of whether coming is worthwhile.
Visa and travel: the 240-hour visa-free transit policy does not cover medical treatment; apply for the appropriate visa category.
On-site evaluation: outpatient consultation, repeat contrast imaging, and laboratory work are usually completed within 1–3 working days.
Multidisciplinary discussion: fix the sequence of resection, ablation, TACE, and systemic therapy.
Starting treatment: ablation or TACE usually means a 3–7 day admission; systemic therapy is mostly outpatient infusion.
Follow-up at home: coordinate with your local doctor; most centers support remote follow-up.
With complete records, most international patients go from arrival to starting treatment within 1–2 weeks; if the plan calls for multiple TACE courses, the whole program may span months — plan split trips or coordinate the sequencing with your home physician.
Honest Notes: Limitations and Risks
Liver cancer treatment depends heavily on staging and liver function, and remote evaluation cannot replace an on-site exam — any "package price" quoted without verified diagnosis is not credible.
Combination regimens such as T+A carry a real side-effect profile (immune hepatitis, gastrointestinal bleeding risk) and need a center with inpatient capability.
Mid-stage TACE usually takes multiple sessions and may eventually stop working; claims of "one procedure solves it" do not match reality.
All prices in this article are order-of-magnitude references from public ranges; actual costs vary by hospital, consumables, and disease.
How to Start
The most pragmatic first step is a remote second opinion: upload your imaging and lab records, and a Chinese hepatobiliary oncologist will assess whether the diagnosis and staging hold, which treatment path fits you, and whether coming to China makes sense. MyMedVia helps international patients connect with hospital international departments, arrange remote consultations, assist with visas and travel, provide full interpretation, and clarify itemized costs. You can submit your records through our contact page to begin.
More articles on cancer treatment — including CAR-T, proton therapy, and other advanced options — are collected on the category page.
This article is general information and does not constitute medical advice. Treatment decisions should follow your staging, liver-function assessment, and your treating physician's judgment.
